Tweets
Yesterdays RheumNow Live Vote survey of 170 Rheumatologists, showed that 74-80% of Rheums are reporting shortages of IV tocilizumab (Actemra) -- TCZ listed by FDA site as a drug in shortage largely due to demand, Genentech says there is supply https://t.co/YAvR4vbVHV
Dr. John Cush @RheumNow ( View Tweet )
4 years 6 months ago
RheumNow Live Vote survey of 159 Rheumatologists shows, because of the Actemra Shortage, Rheums are either changing to subQ TCZ (45%), changing to other biologic or tsDMARD (33%) or waiting for resupply of TCZ (21%). https://t.co/zNeyRsYClD @CreakyJoints https://t.co/aGYO2fqw7J
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 6 months ago
RheumNow Live vote Survey of 161 Rheums shows that in addition to a tocilizumab shortage the main drug shortage is for sulfasalazine (34%) https://t.co/uE856PbF2v @CreakyJoints https://t.co/eCLy3rpjoI
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 6 months ago
GWAS study in RA used to develop polygenic risk score (PRS) for Xray progression (training set = 500 and validated testing set= 740). Risk factors for severe XRAY progr = PRS (P=0.00019), female (P=0.0033), ACPA (P=0.0023), BMI (P=0.031) https://t.co/dwDSnTFUqs
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 6 months ago
Who is Your Glue?
Surely you have used or heard of “<the person> who was the glue that held the family together”.
Read on…
https://t.co/CRaWDQaZvk https://t.co/q8KFcxzzDG
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 6 months ago
Referral Rules for At-Risk Inflammatory Arthritis
https://t.co/p1sBNSmWF5 https://t.co/tk29UNPYdi
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 6 months ago
ONE MILLION DOWNLOADS!
We are excited to announce Dr.Cush and the RheumNow podcast recently hit one million downloads!
Thank you to all of our listeners-we appreciate you coming back week after week.
Find us each week where ever you get your podcasts.
https://t.co/AOJCMGZClJ https://t.co/3ImftCnqzw
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 6 months ago
The next generation of lupus therapies (esp in lupus nephritis) - belimumab, voclosporin , anifrolumab, obinutuzumab. Better trial designs, better organ endpoints, but yet these trials/results are limited by the high dose steroids in play.... https://t.co/48D9rI9EEH
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 6 months ago
How's the United States doing on boosters?
Trailing a long list of countries, including Serbia, Slovenia, and Lithuania
@OurWorldInData https://t.co/cOCVoyuqT3
Eric Topol @EricTopol ( View Tweet )
4 years 6 months ago
UTSW Rheum Grand Rounds
New and concerning: sJIA associated lung disease - rare and associated w/ pulmonary HTN, alveolar proteinosis, high mortality. Unique features: clubbing, eosinophilia, TCZ anaphylaxis, Trisomy 21. Most were Rx w/ IL-1 > IL-6 inhibition @UTSWRheum https://t.co/aJaPurDSmJ
Dr. John Cush @RheumNow ( View Tweet )
4 years 6 months ago
UTSW Rheum Grand Rounds - Dr. Nigrovic shows the efficacy of long acting IL-1 inhibition (canakinumab) and IL-6 (tocilizumab) in systemic JIA patients @UTSWRheum https://t.co/XdG8pAq1c4
Dr. John Cush @RheumNow ( View Tweet )
4 years 6 months ago
UTSW Rheum Grand Rounds
Treating STill's (sJIA) - early early use of anakinra yields best results (in remission and off steroids) - 91% if Anakinra started within the first 3 mos @UTSWRheum https://t.co/neozpYhJtM
Dr. John Cush @RheumNow ( View Tweet )
4 years 6 months ago
